MY194081A - Physiologically balanced injectable formulations of fosnetupitant - Google Patents
Physiologically balanced injectable formulations of fosnetupitantInfo
- Publication number
- MY194081A MY194081A MYPI2018001970A MYPI2018001970A MY194081A MY 194081 A MY194081 A MY 194081A MY PI2018001970 A MYPI2018001970 A MY PI2018001970A MY PI2018001970 A MYPI2018001970 A MY PI2018001970A MY 194081 A MY194081 A MY 194081A
- Authority
- MY
- Malaysia
- Prior art keywords
- fosnetupitant
- physiologically balanced
- injectable formulations
- balanced injectable
- formulations
- Prior art date
Links
- HZIYEEMJNBKMJH-UHFFFAOYSA-N [4-[5-[[2-[3,5-bis(trifluoromethyl)phenyl]-2-methylpropanoyl]-methylamino]-4-(2-methylphenyl)pyridin-2-yl]-1-methylpiperazin-1-ium-1-yl]methyl hydrogen phosphate Chemical compound C=1N=C(N2CC[N+](C)(COP(O)([O-])=O)CC2)C=C(C=2C(=CC=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 HZIYEEMJNBKMJH-UHFFFAOYSA-N 0.000 title abstract 2
- 229950010727 fosnetupitant Drugs 0.000 title abstract 2
- 239000007972 injectable composition Substances 0.000 title 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662345942P | 2016-06-06 | 2016-06-06 | |
| PCT/EP2017/063268 WO2017211663A1 (en) | 2016-06-06 | 2017-06-01 | Physiologically balanced injectable formulations of fosnetupitant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY194081A true MY194081A (en) | 2022-11-11 |
Family
ID=59055193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2018001970A MY194081A (en) | 2016-06-06 | 2017-06-01 | Physiologically balanced injectable formulations of fosnetupitant |
Country Status (36)
| Country | Link |
|---|---|
| US (3) | US10624911B2 (de) |
| EP (2) | EP3435980B1 (de) |
| JP (2) | JP6936817B2 (de) |
| KR (1) | KR102459416B1 (de) |
| CN (1) | CN109310627B (de) |
| AR (1) | AR108676A1 (de) |
| AU (1) | AU2017276588B2 (de) |
| BR (1) | BR112018074655B1 (de) |
| CA (1) | CA3025837C (de) |
| CL (1) | CL2018003338A1 (de) |
| CO (1) | CO2018011686A2 (de) |
| CY (1) | CY1122755T1 (de) |
| DK (1) | DK3435980T3 (de) |
| EA (1) | EA036605B1 (de) |
| EC (1) | ECSP19000169A (de) |
| ES (1) | ES2771226T3 (de) |
| HR (1) | HRP20200196T1 (de) |
| IL (1) | IL263126B (de) |
| JO (1) | JOP20170137B1 (de) |
| LT (1) | LT3435980T (de) |
| MA (1) | MA44513B1 (de) |
| MD (1) | MD3435980T2 (de) |
| MX (1) | MX2018015036A (de) |
| MY (1) | MY194081A (de) |
| PE (1) | PE20190347A1 (de) |
| PH (1) | PH12018502524A1 (de) |
| PL (1) | PL3435980T3 (de) |
| PT (1) | PT3435980T (de) |
| RS (1) | RS59852B1 (de) |
| SG (1) | SG11201809708PA (de) |
| SI (1) | SI3435980T1 (de) |
| TW (1) | TWI725191B (de) |
| UA (1) | UA122285C2 (de) |
| UY (1) | UY37273A (de) |
| WO (1) | WO2017211663A1 (de) |
| ZA (1) | ZA201807932B (de) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11654154B2 (en) | 2019-01-29 | 2023-05-23 | Navinta Iii Inc | Process for preparing injectable Fosaprepitant Dimeglumine compositions having improved storage stability |
| WO2023182388A1 (ja) * | 2022-03-23 | 2023-09-28 | 大鵬薬品工業株式会社 | ホスネツピタント又はその医薬上許容される塩の安定化製剤およびその製造方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL111960A (en) | 1993-12-17 | 1999-12-22 | Merck & Co Inc | Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them |
| DE69428913T2 (de) | 1993-12-29 | 2002-05-29 | Merck Sharp & Dohme | Substituierte morpholinderivate und ihre verwendung als arzneimittel |
| TW385308B (en) | 1994-03-04 | 2000-03-21 | Merck & Co Inc | Prodrugs of morpholine tachykinin receptor antagonists |
| JO2735B1 (en) * | 2003-01-30 | 2013-09-15 | هيلسين هيلث كير أس ايه. | Liquid pharmaceutical formations of balloonosterone |
| US20060167072A1 (en) * | 2004-01-30 | 2006-07-27 | Helsinn Healthcare Sa | Liquid pharmaceutical formulations of palonosetron |
| US20100048607A1 (en) * | 2008-08-25 | 2010-02-25 | Chandrashekhar Kocherlakota | Formulations comprising palonosetron |
| US8426450B1 (en) * | 2011-11-29 | 2013-04-23 | Helsinn Healthcare Sa | Substituted 4-phenyl pyridines having anti-emetic effect |
| PL2866797T3 (pl) * | 2012-07-06 | 2020-11-02 | Pharmathen S.A. | Stabilna, nadająca się do wstrzykiwania kompozycja farmaceutyczna antagonisty receptora neurokininy-1 i sposób jej wytwarzania |
-
2017
- 2017-06-01 ES ES17729822T patent/ES2771226T3/es active Active
- 2017-06-01 DK DK17729822.1T patent/DK3435980T3/da active
- 2017-06-01 EP EP17729822.1A patent/EP3435980B1/de active Active
- 2017-06-01 RS RS20200100A patent/RS59852B1/sr unknown
- 2017-06-01 UA UAA201812842A patent/UA122285C2/uk unknown
- 2017-06-01 CN CN201780034681.5A patent/CN109310627B/zh active Active
- 2017-06-01 WO PCT/EP2017/063268 patent/WO2017211663A1/en active Application Filing
- 2017-06-01 SI SI201730178T patent/SI3435980T1/sl unknown
- 2017-06-01 PL PL17729822T patent/PL3435980T3/pl unknown
- 2017-06-01 PE PE2018003074A patent/PE20190347A1/es unknown
- 2017-06-01 JP JP2018563684A patent/JP6936817B2/ja active Active
- 2017-06-01 MX MX2018015036A patent/MX2018015036A/es active IP Right Grant
- 2017-06-01 BR BR112018074655-0A patent/BR112018074655B1/pt active IP Right Grant
- 2017-06-01 MY MYPI2018001970A patent/MY194081A/en unknown
- 2017-06-01 PT PT177298221T patent/PT3435980T/pt unknown
- 2017-06-01 CA CA3025837A patent/CA3025837C/en active Active
- 2017-06-01 MA MA44513A patent/MA44513B1/fr unknown
- 2017-06-01 EP EP19200383.8A patent/EP3626231A1/de not_active Withdrawn
- 2017-06-01 SG SG11201809708PA patent/SG11201809708PA/en unknown
- 2017-06-01 KR KR1020187034943A patent/KR102459416B1/ko active IP Right Grant
- 2017-06-01 AU AU2017276588A patent/AU2017276588B2/en active Active
- 2017-06-01 LT LTEP17729822.1T patent/LT3435980T/lt unknown
- 2017-06-01 EA EA201892837A patent/EA036605B1/ru unknown
- 2017-06-01 MD MDE20190164T patent/MD3435980T2/ro unknown
- 2017-06-02 AR ARP170101521A patent/AR108676A1/es unknown
- 2017-06-02 UY UY0001037273A patent/UY37273A/es active IP Right Grant
- 2017-06-02 US US15/611,785 patent/US10624911B2/en active Active
- 2017-06-06 JO JOP/2017/0137A patent/JOP20170137B1/ar active
- 2017-06-06 TW TW106118613A patent/TWI725191B/zh active
-
2018
- 2018-11-09 CO CONC2018/0011686A patent/CO2018011686A2/es unknown
- 2018-11-19 IL IL263126A patent/IL263126B/en active IP Right Grant
- 2018-11-22 CL CL2018003338A patent/CL2018003338A1/es unknown
- 2018-11-23 ZA ZA2018/07932A patent/ZA201807932B/en unknown
- 2018-11-29 PH PH12018502524A patent/PH12018502524A1/en unknown
-
2019
- 2019-01-02 EC ECSENADI2019169A patent/ECSP19000169A/es unknown
-
2020
- 2020-02-06 HR HRP20200196TT patent/HRP20200196T1/hr unknown
- 2020-02-10 CY CY20201100123T patent/CY1122755T1/el unknown
- 2020-03-13 US US16/817,683 patent/US11529362B2/en active Active
-
2021
- 2021-08-27 JP JP2021138576A patent/JP7223084B2/ja active Active
-
2022
- 2022-11-15 US US17/986,934 patent/US20230172953A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NI201700137A (es) | Derivados de indol mono o disustituidos como inhibidores de la replicaciãn viral del dengue | |
| CA2956871C (en) | Compounds active towards bromodomains | |
| PH12017502431A1 (en) | Pharmaceutical formulations comprising tenofovir and emtrictabine | |
| MX2016012574A (es) | Compuestos heteroarilo sustituidos y metodos de uso. | |
| EA201792591A1 (ru) | Фармацевтические препараты | |
| PH12016501841A1 (en) | Immunosuppressant formulation | |
| MX2018012618A (es) | Composiciones farmaceuticas orales de mesalazina. | |
| DOP2017000307A (es) | Formulación sólida oral que contiene irinotecán y método de preparación de la misma. | |
| PH12016502243A1 (en) | Pharmaceutical compositions for treating infectious diseases | |
| MX2017016774A (es) | Agente terapeutico para la fibrosis. | |
| PH12018502524A1 (en) | Physiologically balanced injectable formulations of fosnetupitant | |
| CO2018014217A2 (es) | Composiciones farmacéuticas que comprenden safinamida | |
| MX2018005350A (es) | Formulacion de combinacion de dosis fija, eflornitina y sulindaco. | |
| MX2017008879A (es) | Composicion farmaceutica para el tratamiento de la micosis. | |
| PH12018501991A1 (en) | Pharmaceutical composition for use in treating fibrosis | |
| NZ739679A (en) | Cholecalciferol sulfate salts and their use for the treatment of vitamin d deficiency | |
| IN2013MU02015A (de) | ||
| TN2016000561A1 (en) | Stabilized desmopressin | |
| MX367121B (es) | Composición sólida estable de inmunosupresores. | |
| CY1123966T1 (el) | Διαδικασια για την παρασκευη νατριουχου εποπροστενολης ενισχυμενης σταθεροτητας | |
| MX2017001512A (es) | Compuestos activos hacia bromodominios. | |
| AR104570A1 (es) | Métodos de tratamiento de una enfermedad neurodegenerativa | |
| CR20170601A (es) | Formulaciones farmaceuticas que comprenden tenofovir y emtricitabina | |
| IN2014MU00077A (de) | ||
| UA112089C2 (uk) | Тверда лікарська форма комбінованого препарату седативної та снодійної дії, що містить доксиламін |